Asceneuron
The company discovers and develops oral small molecule therapeutics designed to block tau pathology in the brain. Its pipeline targets neurodegenerative disorders with high unmet medical needs, specifically Alzheimer’s disease, Parkinson’s disease, and orphan tauopathies.
Biotechnology
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €27.0M
- Funding rounds
- 1
Investors in Asceneuron
Investors on record for Asceneuron. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Asceneuron?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors